Investment
Features
FeesSafety
Academy
More
Pluang+

SeaStar Medical's CMO Dr. Kevin Chung wins 2026 Combat Nephrology Award for advances in critical care nephrology.

Market News
14 Oct 2026
GlobeNewsWire
View Source
Bullish
SeaStar Medical's CMO Dr. Kevin Chung wins 2026 Combat Nephrology Award for advances in critical care nephrology.

SeaStar Medical announced that its Chief Medical Officer, Dr. Kevin Chung, received the 2026 Combat Nephrology Award for his pioneering work in burn critical care, combat casualty care, and acute organ failure. The award honors contributions bridging military and civilian critical care nephrology, highlighting Dr. Chung's focus on treating destructive hyperinflammation in acute kidney injury (AKI). He will deliver the keynote at the Update in Critical Care Nephrology 2026 conference. SeaStar Medical also promotes its QUELIMMUNE therapy, FDA-approved for pediatric AKI patients, showing promising survival rates and ongoing clinical trials for adult AKI treatment.

SeaStar Medical's Chief Medical Officer Kevin Chung received the 2026 Combat Nephrology Award. For readers following the Health sector, here is Pluang's market snapshot as of Oct 14, 2026 19:01 WIB: 105 of 150 priced US Health stocks rose, 40 fell. Notable movers include LQDA at USD 37.65 (+40.43%), ARWR at USD 61.98 (+6.62%) with a typical hold time of 5 days, and ENVB at USD 1.34 (-4.29%) with a typical hold time of 14 days.

More News

Genesis Global wins Best AI Solution for Software Development at 2026 AI in Capital Markets Awards

Genesis Global wins Best AI Solution for Software Development at 2026 AI in Capital Markets Awards

Genesis Global won the Best AI Solution for Software Development award at the 2026 AI in Capital Markets Awards for its product Genesis Create. This software combines AI with reusable components and financial expertise to help firms develop productio...

Others
Bullish
1 hour ago
nuVizz named Accelerator in 2026 Nucleus Research TMS Value Matrix for last-mile delivery tech

nuVizz named Accelerator in 2026 Nucleus Research TMS Value Matrix for last-mile delivery tech

nuVizz has been recognized as an Accelerator in the 2026 Nucleus Research Transportation Management Value Matrix for its specialized last-mile delivery technology. The platform excels in coordinating complex delivery networks involving private fleets...

Market News
Bullish
1 hour ago
ASML reports strong Q3 2026 EPS of $14.65 on high chip equipment demand despite slight revenue miss.

ASML reports strong Q3 2026 EPS of $14.65 on high chip equipment demand despite slight revenue miss.

ASML Holding posted a strong Q3 2026 earnings per share of $14.65, beating estimates of $12.17, driven by a 55% year-over-year sales growth and a 57.5% gross margin. Although revenue was slightly below expectations at $13.05 billion, the company bene...

Company Fundamentals
Bullish
2 hours ago
Charles Schwab Q3 earnings expected to rise on strong trading and asset management revenue.

Charles Schwab Q3 earnings expected to rise on strong trading and asset management revenue.

Charles Schwab is set to report its Q3 2026 earnings with an estimated EPS of $1.66 and revenue around $7.18-$7.19 billion, reflecting significant growth driven by an 18.2% increase in trading revenue, net interest income, and asset management fees. ...

Company Fundamentals
Bullish
2 hours ago
TSOs prioritize software investments to boost grid security and capacity amid rising demand

TSOs prioritize software investments to boost grid security and capacity amid rising demand

Transmission System Operators (TSOs) are increasingly investing in software like Energy Management Systems and grid planning tools to modernize aging infrastructure, enhance cybersecurity, and expand grid capacity. Cybersecurity remains their top con...

Market News
Neutral
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App